Pharmacological modulation of cytokine action and production through signaling pathways

Cytokine and Growth Factor Reviews

Volumn 9, Issue 3-4, 1998, Pages 239-257

  Young, Peter R ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Agonists; Antagonists; Caspases; Inhibitors; Kinases; Phosphatases; Receptors

Indexed keywords

CYTOKINE;

ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; CELL SURVIVAL; CYTOKINE PRODUCTION; DNA SYNTHESIS; DRUG EFFECT; GENE EXPRESSION; HUMAN; METABOLISM; NONHUMAN; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CYTOKINES; HUMANS; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION;

EID: 0345251973     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(98)00011-2     Document Type: Review

References (171)

1. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998, 392, 565-568.
2. Cairns JS, D'Souza MP. Chemokines and HIV-1 second receptors: the therapeutic connection. Nature Medicine 1998, 4, 563-568.
3. White JR, Lee JM, Young PR, et al. Identification of a potent selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 1998, 273, 10095-10098.
4. Hesselgesser J, Ng HP, May K, et al. Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor. J Biol Chem 1998, 273, 15687-15692.
5. Karpus WJ, Lukacs NW, McRae BL, Stricter RM, Kunkel SL, Miller SD. An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol 1995, 155, 5003-5010.
6. Snowden N, Hajeer A, Thomson W, Ollier B. Lancet 1994, 343, 547-548.
7. Young PR. Protein hormones and their receptors. Curr Opin Biotechnology 1992, 3, 408-421.
8. Davies DR, Wlodawer A. Cytokines and their receptor complexes. FASEB J 1995, 9, 50-56.
9. Wells JA, de Vos AM. Hematopoietic receptor complexes. Annual Review of Biochemistry 1996, 65, 609-634.
10. Samanen JM, Ali FE, Barton LS, et al. J Med Chem 1996, 39, 4867-4870.
11. Sarabu R, Cooper JP, Cook CM, Gillespie P, Perrotta AV, Olson GL. Design and synthesis of small molecule interlueikin-1 receptor antagonists based on a benzene template. Drug design & Discov 1998, 15, 191-198.
12. Akeson AL, Woods CW, Hsieh LC, et al. AF12198, a novel low molecular weight antagonist, selectively binds to the human type I interleukin (IL)-1 receptor and blocks in vivo responses to IL-1. J Biol Chem 1996, 271, 30517-30523.
13. Dower WJ. Targeting growth factor and cytokine receptors with recombinant peptide libraries. Curr Opinion Chem Biol 1998, 2, 328-334.
14. Wrighton NC, Farrrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996, 273, 458-463.
15. Livnah O, Stura EA, Johnson DL, et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8A. Science 1996, 273, 464-471.
16. Wrighton NC, Balasubramanian P, Barbone FP, et al. Increased potency of an erythropoietin peptide mimetic through covalent dimerization. Nature Biotech 1997, 15, 1261-1265.
17. Cwirla SE, Balasubramanian P, Duffin DJ, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997, 276, 1696-1699.
18. Tian S-S, Lamb P, King AG, et al. A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor. Science 1998, 281, 257-259.
19. Fry DW, Bridges AJ. Inhibitors of protein tyrosine kinases. Curr Opin Biotech 1995, 6, 662-667.
20. Levitzki A. Targeting signal transduction for disease therapy. Curr Opin Cell Biology 1996, 8, 239-244.
21. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995, 267, 1782-1788.
22. Mohammadi M, McMahon G, Sun L, et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997, 276, 955-960.
23. Fry DW, Krake AJ, McMichael A, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1995, 265, 1093-1095.
24. Buchdunger E, Zimmermann J, Mett H, et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA 1995, 92, 2558-2562.
25. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. American Journal of Respiratory & Critical Care Medicine 1998, 157, 351-370.
26. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995, 75, 725-748.
27. Semmler J, Wachtel H, Endres S. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-a production by human mononuclear cells. Int J Immunopharmacol 1993, 15, 409-410.
28. Molnar KK, Yonno L, Heaslip R, Weichman B. Modulation of TNF alpha and IL-1 beta from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents & Actions 1993, 39, C77-C79.
29. Prabhakar U, Lipshutz D, Bartus JO, et al. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. International Journal of Immunopharmacology 1994, 16, 805-816.
30. Verghese MW, McConnell RT, Strickland AB, et al. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. Journal of Pharmacology & Experimental Therapeutics 1995, 272, 1313-1320.
31. Harbinson PL, MacLeod D, Hawksworth R, et al. The effect of a novel orally-active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic patients. Eur Resp J 1997, 10, 1008-1014.
32. Matsumori A. The use of cytokine inhibitors. A new therapeutic insight into heart failure. International Journal of Cardiology 1997, 62, S3-S12.
33. Liu K, Gaffen SL, Goldsmith MA. JAK/STAT signaling by cytokine receptors. Curr Opin Immunol 1998, 10, 271-278.
34. Leonard WJ, O'Shea JJ. JAKS and STATS: Biological implications. Annu Rev Immunol 1998, 16, 293-322.
35. O'Shea JJ. Jaks, STATs, Cytokine Singal Transduction, and Immunoregulation: Are we there yet? Immunity 1997, 7, 1-11.
36. Xu X, Sun YL, Hoey T. Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain. Science 1996, 273, 794-797.
37. Bhattacharya S, Eckner R, Grossman S, et al. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha. Nature 1996, 383, 344-347.
38. Zhang JJ, Vinkemeier U, Gu W, Chakravarti D, Horvath CM, Darnell JEJ. Two contact regions between Stat1 and CBP/p300 in interferon gamma signaling. Proc Natl Acad Sci USA 1996, 93, 15092-15096.
39. Horvai AE, Xu L, Korzus E, et al. Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300. Proc Natl Acad Sci USA 1996, 94, 1074-1079.
40. Look DC, Pelletier MR, Tidwell RM, Roswit WT, Holtzman MJ. Stat1 depends on transcriptional synergy with Sp1. J Biol Chem 1995, 270, 264-267.
41. Schaefer TS, Sanders LK, Nathans D. Cooperative transcriptional activity of Jun and Stat3 beta, a shhort form of Stat3. Proc Natl Acad Sci USA 1995, 92, 9097-9101.
42. Stocklin E, Wissler M, Gouilleux F, Groner B. Functional interactions between Stat5 and the glucocorticoid receptor. Nature 1996, 383, 726-728.
43. Zhang X, Blenis J, Li HC, Schindler C, Chen-Kiang S. Requirement for serine phosphorylation for formation of STAT-promoter complexes. Science 1995, 267, 1990-1994.
44. Wen Z, Zhong Z, Darnel JEJ. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995, 82, 241-250.
45. Nicholson SE, Hilton DJ. The SOCS proteins: a new family of negative regulators of signal transduction. Journal of Leukocyte Biology 1998, 63, 665-668.
46. Meydan N, Grunberger T, Dadi H, et al. Inhibition of acute lymphoblastic leukemia by a Jak-2 inhibitor. Nature 1996, 379, 645-648.
47. Rui H, Xu J, Mehta S, et al. Activation of the Jak2-Stat5 signaling pathway in Nb2 lymphoma cells by an anti-apoptotic agent, aurintricarboxylic acid. J Biol Chem 1998, 273, 28-32.
48. Brown MT, Cooper JA. Regulation, structures and functions of src. Biochem Biophys Acta 1996, 1287, 121-149.
49. Thomas SM, Brugge JS. Cellular functions regulated by src family kinases. Annu Rev Cell Dev Biol 1997, 13, 513-609.
50. Pawson T. Protein modules and signalling networks. Nature 1995, 373, 573-580.
51. Pawson T, Scott JD. Signaling through scaffold, anchoring, and adaptor proteins. Science 1997, 278, 2075-2080.
52. Feng GS, Pawson T. Phosphotyrosine phosphatases with SH2 domains: regulators of signal transduction. Trends Genet 1994, 10, 54-58.
53. Bolen JB, Brugge JS. Leukocyte protein tyrosine kinases: potential targets for drug discovery. Annual Review of Immunology 1997, 15, 371-404.
54. Eck MJ, Pluskey S, Trub T, Harrison SC, Shoelson SE. Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2. Nature 1996, 379, 277-280.
55. Hatada MH, Lu XL, Laird ER, et al. Molecular basis for the interaction of the protein tyrosine kinase ZAP-70 with the T cell receptor. Nature 1995, 377, 32-38.
56. Hanke JH, Gardner JP, Dow RL, et al. J Biol Chem 1996, 271, 695-701.
57. Woscholski R, Parker PJ. Inositol lipid 5-phosphatases - traffic signals and signal traffic. Trends Biochem Sci 1997, 22, 427-431.
58. Vanhaesbroeck B, Leevers SJ, Panayotoy G, Waterfield MD. Phosphoinositide 3 kinases: a conserved family of signal transducers. Trends Biochem Sci 1997, 22, 276-272.
59. Duronio V, Scheid MP, Ettinger S. Downstream signalling events regulated by phosphatidylinositol 3-kinase activity. Cell Signal 1998, 10, 233-239.
60. Lemmon M, Ferguson KM, Schlessinger J. PH domains: diverse sequences with a common fold recruit signalling molecules to the cell surface. Cell 1996, 85, 621-624.
61. Bellacosa A, Franke TF, Gonzalez-Portal ME, et al. Oncogene 1993, 8, 745-754.
62. Alessi DR, Cohen P. Mechanism of activation and function of protein kinase B. Curr Opin Genet Develop 1998, 8, 55-62.
63. Klippel A, Kavanaugh WM, Pot D, Williams LT. A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its plekstrin homology domain. Mol Cell Biol 1997, 17, 338-344.
64. Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr Biol 1997, 7, 261-269.
65. Andjelkovic M, Alessi DR, Meier R, et al. Role of translocation in the activation and function of protein kinase B. J Biol Chem 1997, 272, 31515-31324.
66. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/akt cell survival pathway. J Biol Chem 1998, 273, 19929-19932.
67. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997, 278, 687-689.
68. Ahmed NN, Grimes HL, Bellacosa A, Chan TO, Tsichlis PN. Transduction of interleukin-2 anti-apoptotic and proliferative signals via Akt protein kinase. Proc Natl Acad. Sci USA 1997, 94, 3627-3632.
69. Grandori C, Eisenman RN. Myc target genes. Trends Biochem Science 1997, 22, 177-181.
70. Thelen M, Wymann MP, Langen H. Wortmannin binds specifically to 1-phosphatidylinositol 3-kinase while inhibiting guanine nucleotide-binding protein-coupled receptor signaling in neutrophil leukocytes. Proc Natl Acad Sci USA 1994, 91, 4960-4964.
71. Vlahos CJ, Matter WF, Hui KY, Brown RF. J Biol Chem 1994, 269, 5241-5248.
72. Patki V, Lawe DC, Corvera S, Virbasius JV, Chawla A. A functional PtdIns(3)P-binding motif. Nature 1998, 394, 433-434.
73. Gaullier J-M, Simonsen A, D'Arrigo A, Bremnes B, Stenmark H, Aasland R. FYVE fingers bind PtdIns(3)P. Nature 1998, 394.
74. Kelly PA, Gruber SA, Behbod F, Kahan BD. Sirolimus, a new, potent immunosuppressive agent. [Review] [74 refs]. Pharmacotherapy 1997, 17, 1148-1156.
75. Cafferkey R, Young PR, McLaughlin M, et al. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and vps34 abrogate rapamycin cytotoxicity. Mol Cell Biol 1993, 13, 6012-6023.
76. Kunz J, Henriquez R, Schneider U, Deuter-Reinhard M, Movva NR, Hall MN. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 1993, 73, 585-596.
77. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994, 78, 35-43.
78. Stan R, McLaughlin MM, Cafferkey R, Johnson RK, Rosenberg M, Livi GP. Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue. Journal of Biological Chemistry 1994, 269, 32027-32030.
79. Abraham RT. Phosphatidylinositol 3-kinase related kinases. Current Opinion in Immunology 1996, 8, 412-418.
80. Brunn GJ, Hudson CC, Sekulic A, et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 1997, 277, 99-101.
81. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC, Jr., Abraham RT. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO Journal 1996, 15, 5256-5267.
82. Thomas G, Hall MN. TOR signalling and control of cell growth. Curr Opin Cell Biology 1997, 9, 782-787.
83. Ruhlmann A, Nordheim A. Effects of the immunosuppressive drugs CsA and FK506 on intracellular signalling and gene regulation. Immunobiology 1997, 198, 192-206.
84. Braun W, Kallen J, Mikol V, Walkinshaw MD, Wuthrich K. Three-dimensional structure and actions of immunosuppressants and their immunophilins. FASEB Journal 1995, 9, 63-72.
85. Liu J, Farmer JD, Jr., Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991, 66, 807-815.
86. Klee CB, Ren H, Wang X. Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. Journal of Biological Chemistry 1998, 273, 13367-13370.
87. Stoddard BL, Flick KE. Calcineurin-immunosuppressor complexes. Current Opinion in Structural Biology 1996, 6, 770-775.
88. Dumont FJ, Staruch MJ, Koprak SL, et al. The immunosuppressive and toxic effect of FK506 are mechanistically related: pharmacology of a novel antagonist of FK506 and rapamycin. J Exp Med 1992, 176, 751-760.
89. Su Q, Weber L, Le Hir M, Zenke G, Ryffel B. Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase. Renal Physiol Biochem 1995, 18, 128-139.
90. Cai W, Hu L, Foulkes JG. Transcription-modulating drugs: mechanism and selectivity. Curr Opin Biotech 1996, 7, 608-615.
91. Ghosh S, May MJ, Kopp EB. NF-kB and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998, 16, 225-260.
92. Baldwin ASJ. The NF-kB and IkB proteins: new discoveries and insights. Annu Rev Immunol 1996, 14, 649-681.
93. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IκB kinase that activates the transcription factor NF-κB [see comments]. Nature 1997, 388, 548-554.
94. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. The IκB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IκB phosphorylation and NF-κB activation. Cell 1997, 91, 243-252.
95. Mercurio F, Zhu H, Murray BW, et al. IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation [see comments]. Science 1997, 278, 860-866.
96. Nakano H, Shindo M, Sakon S, et al. Differential regulation of IκB kinase alpha and beta by two upstream kinases, NF-κB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci USA 1998, 95, 3537-3542.
97. Ling L, Cao Z, Goeddel DV. NF-κB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. Proc Natl Acad Sci USA 1998, 95, 3792-3797.
98. Baeuerle PA. Pro-inflammatory signaling: last pieces in the NF-KB puzzle? Current Biology 1998, 8, R19-R22.
99. O'Neill LA, Greene C. Signal transduction pathways activated by the IL-1 receptor family: ancient signaling machinery in mammals, insects, and plants. Journal of Leukocyte Biology 1998, 63, 650-657.
100. Burns K, Martinon F, Esslinger C, et al. MyD88, an adapter protein involved in interleukin-1 signaling. Journal of Biological Chemistry 1998, 273, 12203-12209.
101. Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997, 278, 1612-1615.
102. Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 1997, 7, 837-847.
103. Parnham MJ. Inflammation: From molecular biology to clinic. Drug News Perspect 1998, 11, 44-51.
104. Thornberry NA. The caspase family of cysteine proteases. British Medical Bulletin 1997, 53, 478-490.
105. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends in Biochemical Sciences 1997, 22, 299-306.
106. Miller DK. The role of the Caspase family of cysteine proteases in apoptosis. Seminars in Immunology 1997, 9, 35-49.
107. Cohen GM. Caspases: the executioners of apoptosis. Biochemical Journal 1997, 326, 1-16.
108. Wallach D. Cell death induction by TNF: a matter of self control. Trends Biochem Sci 1997, 22, 107-109.
109. Wallach D, Kovalenko AV, Varfolomeev EE, Boldin MP. Death-inducing functions of ligands of the tumor necrosis factor family: a Sanhedrin verdict. Curr Opin Immunol 1998, 10, 279-288.
110. Thome M, Hofmann K, Burns K, et al. Identification of CARDIAK, a RIP-like kinase that associates with caspase-1. Curr Biol 1998, 8, 885-888.
111. Baichwal VR, Baeuerle PA. Activate NF-κ B or die? Current Biology 1997, 7, R94-R96.
112. Villa P, Kaufmann SH, Earnshaw WC. Caspases and caspase inhibitors. Trends in Biochemical Sciences 1997, 22, 388-393.
113. Kumar S, McDonnell PC, Gum RJ, Hand AT, Lee JC, Young PR. Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun 1997, 235, 533-538.
114. Gupta S, Barrett T, Whitmarsh AJ, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 1996, 15, 2760-2770.
115. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997, 9, 180-186.
116. Kyriakis JM, Avruch J. Sounding the alarm: protein kinase cascades activated by stress and inflammation. J Biol Chem 1996, 271, 24313-24316.
117. Deak M, Clifton AD, Lucocq JM, Alessi DR. Mitogen and Stress Activated Protein kinase (MSK1), a novel two-kinase domain enzyme that is directly activated by MAPK and SAPK2/p38, and which may mediate the activation of CREB. Embo J 1998, 17, In press.
118. Fukunaga R, Hunter T. MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. Embo J 1997, 16, 1921-1933.
119. Waskiewicz AJ, Flynn A, Proud CG, Cooper JA. Mitogen-activated protein kinases activate the serine/threonine kinases Mnkl and Mnk2. Embo J 1997, 16, 1909-1920.
120. Cuenda A, Rouse J, Doza YN, et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 1995, 364, 229-233.
121. Morrison DK, Cutler REJ. The complexity of Raf-1 regulation. Curr Opin Cell Biol 1997, 9, 174-179.
122. Rothe M, Regnier C, Woronicz J, et al. NF-kB activation by TNF. J Interferon Cytokine Res 1998, 18, A-49.
123. Cohen P. The search for physiological substrates of MAP and SAP kinases in mammalian cells. Trends Cell Biol 1997, 7, 353-361.
124. Alessi DA, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase in vitro and in vivo. J Biol Chem 1995, 270, 27489-27494.
125. Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a Novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998, 273, 18623-18632.
126. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372, 739-746.
127. Young PR, McLaughlin MM, Kumar S, et al. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem 1997, 272, 12116-12121.
128. Wilson KP, McCaffrey PG, Hsiao K, et al. The Structural Basis for the Specificity of Pyridinylimidazole Inhibitors of p38 MAP kinase. Chem Biol 1997, 4, 423-431.
129. Wang Z, Canagarajah BJ, Boehm JC, et al. How protein kinases can be specific. Structure 1998:In press.
130. Tong L, Pav S, White DM, et al. A Highly Specific Inhibitor of Human p38 MAP Kinase Binds in the ATP pocket. Nat Struct Biol 1997, 4, 311-316.
131. Gum RJ, McLaughlin MM, Kumar S, et al. Acquistion of sensitivity of stress-activated Protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J Biol Chem 1998, 273, 15605-15610.
132. Eyers PA, Craxton M, Morrice N, Cohen P, Goedert M. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino acid substitution. Chem Biol 1998, 5, 321-328.
133. Price MA, Cruzalegui FH, Treisman R. The p38 and ERK MAP kinase pathways cooperate to activate Ternary Complex Factors and c-fos transcription in response to UV light. Embo J 1996, 15, 6552-6563.
134. Karin M, Liu Z-g, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997, 9, 240-246.
135. Han J, Jiang Y, Li Z, Kravchenko VV, Ulevitch RJ. Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature 1997, 386, 296-299.
136. Minden A, Karin M. Regulation and function of the JNK subgroup of MAP kinases. Biochim Biophys Acta 1997, 1333, F85-F104.
137. Hazzalin CA, Cano E, Cuenda A, Barratt MJ, Cohen P, Mahadevan LC. p38/Rk is essential for stress-induced nuclear responses: Jnk/Sapks and c-Jun/Atf-2 phosphorylation are insufficient. Curr Biol 1996, 6, 1028-1031.
138. Hazzalin CA, Cuenda A, Cano E, Cohen P, Mahadevan LC. Effects of the inhibition of p38/RK MAP kinase on induction of five fos and jun genes by diverse stimuli. Oncogene 1997, 15, 2321-2331.
139. Kato S, Endoh H, Masuhiro Y, et al. Activation of estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995, 270, 1491-1494.
140. David M, Petricoin EI, Benjamin C, Pine R, Weber MJ, Larner AC. Requirement for MAP kinase (ERK2) activity in interferon a and interferon b stimulated gene expression through STAT proteins. Science 1995, 269, 1721-1723.
141. Kumar S, Orsini MJ, Lee JC, McDonnell PC, Debouck C, Young PR. Activation of the HIV-1 long terminal repeat by cytokines and environmental stress requires an active CSBP/p38 MAP kinase. J Biol Chem 1996, 271, 30864-30869.
142. Beyaert R, Cuenda A, Vanden Berghe W, et al. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. Embo J 1996, 15, 1914-1923.
143. 2-terminal kinase pathway. Science 1998, 280, 1945-1949.
144. Young P, McDonnell P, Dunnington D, Hand A, Laydon J, Lee J. Pyridinyl imidazoles inhibit IL-1 and TNF production at the protein level. Agents & Actions 1993, 39, C67-C69.
145. Prichett W, Hand A, Sheilds J, Dunnington D. Mechanism of action of bicyclic imidazoles defines a translational regulatory pathway on tumor necrosis factor α. J Inflamm 1995, 45, 97-105.
146. Swantek JL, Cobb MH, Geppert TD. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK. Mol Cell Biol 1997, 17, 6274-6282.
147. Huot J, Houle F, Marceau F, Landry J. Oxidative stress-induced actin reorganization mediated by the p38 mitogen-activated protein kinase/heat shock protein 27 pathway in vascular endothelial cells. Circ Res 1997, 80, 383-392.
148. Kramer RM, Roberts EF, Um SL, et al. p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPla2) in thrombin-stimulated platelets. Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPla2. J Biol Chem 1996, 271, 27723-27729.
149. Griswold DE, Young PR. Pharmacology of cytokine suppressive anti-inflammatory drug binding protein (CSBP), a novel stress induced kinase. Pharmacol Commun 1996, 7.
150. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996, 279, 1453-1461.
151. Jackson JR, Bolognese B, Hillegass L, et al. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther 1998, 284, 687-692.
152. Yang DD, Kuan CY, Whitmarsh AJ, et al. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 1997, 389, 865-870.
153. Gibbs JB, Oliff A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annual Review of Pharmacology & Toxicology 1997, 37, 143-166.
154. Barnes PJ, Pederen S, Busse W. Efficacy and safety of inhaled corticosteroids. Am J Respir Crit Care Med 1998, 157, S1-S53.
155. Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? [comment]. Cell 1998, 93, 487-490.
156. Heck S, Kullman M, Gast A, et al. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. Embo J 1994, 13, 4087-4095.
157. Reichardt HM, Kaestner KH, Tuckermann J, et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998, 93, 531-541.
158. Vayssiere BM, Dupont S, Choquart A, et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 1997, 11, 1245-1255.
159. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Reviews 1998, 50, 151-196.
160. Hughes DE, Dai A, Tifee JC, Li HH, Mundy GR, Boyce BF. Estrogen promotes apoptosis of murine osteoclasts mediated by TGFb. Nature Medicine 1996, 2, 1132-1136.
161. Girasole G, Jilka RL, Passeri G, et al. 17b-estradiol inhibits IL-6 production by bone marrow-derived stromal cells and osteoblasts it vitro, a potential mechanism for the antosteoporotic effect of estrogens. J Clin Invest 1992, 89, 883-891.
162. Spiegelman BM. PPARg in monocytes: less pain, any gain? Cell 1998, 93, 153-155.
163. Jiang C, Ting AT, Seed B. PPARg agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391, 82-86.
164. Kumar A, Dhawan S, Hardegen NJ, Aggarwal BB. Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-κB activation. Biochemical Pharmacology 1998, 55, 775-783.
165. Chaturvedi MM, Kumar A, Darnay BG, Chainy GB, Agarwal S, Aggarwal BB. Sanguinarine (pseudochelerythrine) is a potent inhibitor of NF-κB activation, IκBalpha phosphorylation, and degradation. Journal of Biological Chemistry 1997, 272, 30129-30134.
166. Schwenger P, Alpert D, Skolnik EY, Vilcek J. Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IκB alpha phosphorylation and degradation. Molecular & Cellular Biology 1998, 18, 78-84.
167. Sampaio EP, Sarno EP, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J Exp Med 1991, 173, 699-703.
168. Sampaio EP, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993, 168, 408-414.
169. + subset. J Exp Med 1998, 187, 1885-1892.
170. Eigler A, Sinha B, Hartmann G, Endres S. Taming TNF: strategies to restrain this proinflammatory cytokine. Immunology Today 1997, 18, 487-492.
171. Lee JC, Prabhakar U, Griswold DE, Dunnington D, Young PR, Badger A. Small Molecular Weight TNF Biosynthesis Inhibitors: Strategies and Prospectives. Circul Shock 1995, 44, 97-103.